Abstract: Atopic dermatitis(AD) is a chronic inflammatory skin disease with heterogeneous characteristics. Different treatment schemes are adopted according to mild, moderate and severe AD patients. It's significant to precise determination of the severity of AD for the proposal of treatment. Currently, the decision of severity still depends on scoring atopic dermatitis and eczema area and severity index. It is challenging to accurately predict the outcome and recurrence of the ailment. In recent years, research on clinical biomarkers of the severity of AD has made some development. The research mainly focuses on chemokines(such as CCL17), interleukins(such as IL-31, IL-17), etc. From the perspective of the relationship between biomarkers and the pathogenesis of AD and the degree of severity, the research progress of related markers is summarized, and it is hoped to provide a certain basis for clinical diagnosis and treatment.